Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial-Reference-Cited by-同舟云学术

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial

Published:2023-10 Issue:10 Volume:29 Page:1345-1354
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

KHAN MUHAMMAD SHAHZEB,ANKER STEFAN D.,FILIPPATOS GERASIMOS,FERREIRA JOÃO PEDRO,POCOCK STUART J.,JANUZZI JAMES L.,CHOPRA VIJAY K.,PIÑA ILEANA L.,BÖHM MICHAEL,PONIKOWSKI PIOTR,VERMA SUBODH,BRUECKMANN MARTINA,VEDIN OLA,PEIL BARBARA,ZANNAD FAIEZ,PACKER MILTON,BUTLER JAVED

Funder

Boehringer Ingelheim International GmbH

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

2. Cardiovascular and renal outcomes with Empagliflozin in heart failure;Packer;N Engl J Med,2020

3. Sotagliflozin in patients with diabetes and recent worsening heart failure;Bhatt;N Engl J Med,2021

4. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis;Butler;ESC Heart Fail,2020

5. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial;Anker;Circulation,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07